Abstract 2164: Impact of Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent on the Outcome of Patients with Sirolimus-Eluting Stent Failure: Multicenter Registry in Asia
Purpose: To evaluate the Sirolimus-eluting stent (SES) and Paclitaxel-eluting stent (PES) on the outcome of patients with SES failure (SES-F).
Methods: A total of 520 patients with 609 SES-F lesions (male 74.8%, mean age 72.1 yrs, LMT 7.1%, LAD 47.6%, LCX 25.0%, RCA 16.2%, SVG 4.1%) were treated with SES (mean lesion length 26.1±12.6 mm, mean stent length 31.3±15.9mm) and PES (mean lesion length 28.3±12.2 mm, mean stent length 32.9±19.3 mm). We evaluate immediate and long-term clinical results by 6 and 12 months angiography.
Results: The baseline clinical characteristics between 2 groups were similar. See table for clinical results.
Conclusion: The use of SES and PES in patients with restenosis after SES implantation was safe with low complications. Patients treated with SES showed lesser rate of restenosis compared with PES.